Padlock Therapeutics

Exploring the full biological and therapeutic footprint of protein deimination

Padlock Therapeutics is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs.

Padlock was acquired by Bristol Myers Squibb in 2016.